[1] Steinman RM, Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J Exp Med. 1973;137(5):1142-1162.
[2] Mackern-Oberti JP, Llanos C, Vega F, et al. Role of dendritic cells in the initiation, progress and modulation of systemic autoimmune diseases. Autoimmun Rev. 2015;14(2):127-139.
[3] Park MJ, Park KS, Park HS, et al. A distinct tolerogenic subset of splenic IDO(+)CD11b(+) dendritic cells from orally tolerized mice is responsible for induction of systemic immune tolerance and suppression of collagen-induced arthritis. Cell Immunol. 2012;278(1-2):45-54.
[4] Moussion C, Girard JP. Dendritic cells control lymphocyte entry to lymph nodes through high endothelial venules. Nature. 2011;479(7374):542-546.
[5] Lechler RI, Sykes M, Thomson AW, et al. Organ transplantation: how much of the promise has been realized? Nat Med. 2005;11:605-613.
[6] Morelli AE, Thomson AW. Tolerogenic dendritic cells and the quest for transplant tolerance. Nat Rev Immunol. 2007;7: 610-621.
[7] Inaba K, Swiggard WJ, Steinman RM, et al. Isolation of dendritic cells. Curr Protoc Immunol, 2009; chapter 3, Unit 3.7.
[8] Matsue H, Yang C, Matsue K, et al. Contrasting impacts of immunosuppressive agents (rapamycin, FK506, cyclosporin A, and dexamethasone) on bidirectional dendritic cell-T cell interaction during antigen presentation. J Immunol. 2002; 169(7):3555-3564.
[9] Morel PA, Butterfield LH. Dendritic cell control of immune responses. Front Immunol. 2015;6:42.
[10] Poirier N, Blancho G, Vanhove B. A more selective costimulatory blockade of the CD28-B7 pathway. Transpl Int. 2011;24(1):2-11.
[11] Vogel I, Kasran A, Cremer J, et al. CD28/CTLA-4/B7 costimulatory pathway blockade affects regulatory T-cell function in autoimmunity. Eurol J Immunol. 2015.
[12] Sharpe AH, Freeman G J. The B7-CD28 superfamily. Nat Rev Immunol. 2002;2(2):116-126.
[13] Iwasaki A, Medzhitov R. Control of adaptive immunity by the innate immune system. Nat Immunol, 2015;16(4):343-353.
[14] Ribot JC, Debarros A, Mancio-Silva L, et al. B7-CD28 costimulatory signals control the survival and proliferation of murine and human γδ T cells via IL-2 production. J Immunol. 2012;189(3):1202-1208.
[15] Turnquist HR, Raimondi G, Zahorchak AF, et al. Rapamycin- conditioned dendritic cells are poor stimulators of allogeneic CD4+ T cells, but enrich for antigen-specific Foxp3+ T regulatory cells and promote organ transplant tolerance. J Immunol. 2007;178(11):7018-7031.
[16] Macedo C, Turquist H, Metes D, et al. Immunoregulatory properties of rapamycin-conditioned monocyte-derived dendritic cells and their role in transplantation. Transplant Res. 2012;28(1):16.
[17] Zaccard CR, Watkins SC, Kalinski P,et al. CD40L induces functional tunneling nanotube networks exclusively in dendritic cells programmed by mediators of type 1 immunity. J Immunol. 2015;294(3):1047-1056.
[18] Woltman AM, de Fijter JW, Kamerling SW, et al. The effect of calcineurin inhibitors and corticosteroids on the differentiation of human dendritic cells. Eur J Immunol. 2000;30(7): 1807- 1812.
[19] Lee JI, Ganster RW, Geller DA, et al. Cyclosporine A inhibits the expression of costimulatory molecules on in vitro-generated dendritic cells: association with reduced nuclear translocation of nuclear factor kappa B. Transplantation. 1999;68(9):1255-1263.
[20] Dupuy P, Bagot M, Michel L, et al. Cyclosporin A inhibits the antigen-presenting functions of freshly isolated human Langerhans cells in vitro. J Invest Dermatol. 1991;96(4):408- 413.
[21] Varey AM, Champion BR, Cooke A. Cyclosporine affects the function of antigen-presenting cells. Immunology. 1986;57(1): 111-114.
[22] Roberts MS, Knight SC. Low-dose immunosuppression by cyclosporine operating via antigen-presenting dendritic cells. Transplantation. 1990;50(1):91-95.
[23] Szabo G, Gavala C, Mandrekar P. Tacrolimus and cyclosporine A inhibit allostimulatory capacity and cytokine production of human myeloid dendritic cells. J Investig Med. 2001;49(5):442-449.
[24] Lee SJ, Song L, Yang MC, et al. Local administration of granulocyte macrophage colony-stimulating factor induces local accumulation of dendritic cells and antigen-specific CD8+ T cells and enhances dendritic cell cross-presentation. Vaccine. 2015;33(13):1549-55.
[25] Amiel E, Everts B, Fritz D, et al. Mechanistic target of rapamycin inhibition extends cellular lifespan in dendritic cells by preserving mitochondrial function. J Immunol. 2014;193(6): 2821-2830.
[26] Chiang PH, Wang L, Liang Y, et al. Inhibition of IL-12 signaling Stat4/IFN-gamma pathway by rapamycin is associated  with impaired dendritic cell function. Transplant Proc. 2002;34(5): 1394-1395.
[27] Coates PT, Colvin BL, Kaneko K, et al. Pharmacologic, biologic, and genetic engineering approaches to potentiation of donor-derived dendritic cell tolerogenicity. Transplantation. 2003;75(9 Suppl):32S-36S.
[28] Lee YR, Yang IH, Lee YH, et al. Cyclosporin A and tacrolimus, but not rapamycin, inhibit MHC-restricted antigen presentation pathways in dendritic cells. Blood. 2005;105(10): 3951-3955.
[29] Mehling A, Grabbe S, Voskort M, et al. Mycophenolate mofetil impairs the maturation and function of murine dendritic cells. J Immunol. 2000;165(5):2374-2381.
[30] Cicinnati VR, Hou J, Lindemann M, et al. Mycophenolic acid impedes the antigen presenting and lymph node homing capacities of human blood myeloid dendritic cells. Transplantation. 2009;88(4):504-513.
[31] Kambayashi T, Wallin RP, Ljunggren HG. cAMP-elevating agents suppress dendritic cell function. J Leukoc Biol. 2001; 70(6):903-910.